Key result
Implantable cardioverter defibrillator deactivation and nonreplacement in older patients require clear ethical and legal guidelines and early end-of-life planning discussions.
Discussing ICD deactivation and non-replacement during the initial consent process is recommended to address ethical and legal challenges as patients age and develop comorbidities.
Supports incorporating deactivation planning into initial ICD consent; leaves open standardized ethical-legal frameworks pending further consensus.
PURPOSE OF REVIEW: Implantable cardioverter defibrillator (ICD) implantation has become a common and standard treatment for primary and secondary prevention of sudden cardiac death in patients with poor left ventricular ejection fraction across the world. Circumstances, of course, change after the initial implant as patients age. This raises legal and ethical questions about deactivating or not replacing ICD generators when the likelihood of meaningful benefit has diminished. RECENT FINDINGS: Health professionals are reluctant to discuss the end-of-life planning with patients who have ICDs. Older patients are more likely to have multiple comorbidities that worsen or accumulate further after initial implantation and attenuate the survival benefit of ICDs. Joint guidelines suggest physicians educate patients during the initial consent process about the possibility of deactivating ICDs after implantation if their individual situation changes to the point of futility. SUMMARY: ICD deactivation and nonreplacement are unavoidable issues that require clarity for meaningful and ethical implementation. This is an ongoing process.
No takes yet. Share an insight, caveat, or question.
Wright et al. (2012) conducted a review in Sudden cardiac death prevention in patients with poor left ventricular ejection fraction. Implantable cardioverter defibrillator (ICD) deactivation or nonreplacement was evaluated. Implantable cardioverter defibrillator deactivation and nonreplacement in older patients require clear ethical and legal guidelines and early end-of-life planning discussions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: